Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Pasithea
Innovative non-invasive device offers hope for effective sleep apnea treatment

Pasithea improves treating obstructive sleep apnea (OSA), a condition affecting millions worldwide. Traditional treatments like continuous positive airway pressure (CPAP) face high refusal and dropout rates. Pasithea offers a non-invasive solution based on triggered kinesthetic stimulation. By detecting early signs of apnea or hypopnea and inducing a controlled response, Pasithea activates muscle control centers to prevent oxygen desaturation and associated cardiovascular risks, aiming to improve patient compliance and outcomes.

Active
🇫🇷 France
Pasithea
FlowView Diagnostics
Accurate and fast monitoring of leukemia patients

FlowView Diagnostics addresses the challenge of analyzing complex cell data from blood samples using multiparameter flow cytometry, vital for conditions like leukemia monitoring. They tackle this with an algorithm that quickly processes raw data, detecting Minimal Residual Disease (MRD) more accurately and rapidly than manual methods. In a case study, the algorithm analyzed 8 million cells in 2 minutes, presenting simplified results for quicker interpretation, reducing the risk of false negatives, and enhancing efficiency in leukemia monitoring.

Active
🇳🇱 Netherlands
FlowView Diagnostics
Asclepius
Revolutionizing pre- and post-operative surgical assessment

The rising number of surgeries in healthcare systems like the National Health Service is challenging due to increasing demand and backlogs. However, new solutions like the Asclepius Platform aim to streamline assessments before and after surgery using digital tools and AI. By analyzing patient data, it helps doctors make better decisions, reduce complications, and improve patient outcomes. Designed with input from patients, it's a cost-effective way to make surgery safer and more efficient.

Active
🇬🇧 United Kingdom
Asclepius
Lamina
The solution for effective cartilage regeneration

Lamina offers a solution for the regeneration of cartilage, addressing a prevalent issue affecting millions worldwide. Traditional treatments focus on symptom management or procedures like joint replacement, with limited success. Lamina's ARTiREG, enhances cell therapy with a special framework to hold Mesenchymal stem cells which repair for the body and help fix damaged cartilage. This patented approach promotes fast recovery, potentially transforming outcomes for individuals with cartilage damage.

Active
🇫🇷 France
Lamina
Hemeo
Blood clotting management in critical care

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

Active
🇳🇱 Netherlands
Hemeo
Concord Neonatal
A shock-free birth for every baby

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

Active
🇳🇱 Netherlands
Concord Neonatal
Foveo FERTILITY
Enhancing assisted fertility through optimal environment control

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

Active
🇬🇧 United Kingdom
Foveo FERTILITY
NC Biomatrix
Regeneration of intervertebral disc as treatment for low back pain

NC Biomatrix offers a solution for treating chronic back pain caused by intervertebral disc degeneration. Current treatments only address symptoms, have limited effectiveness and often come with complications. NC Biomatrix introduces a new approach using a bio-inductive protein extract obtained from porcine notochordal biomatrix. This injectable treatment addresses the underlying pathology and aims to restore the degenerated disc as a way to definitively treat chronic back pain.

Active
🇳🇱 Netherlands
NC Biomatrix

Our impact

15
Countries active in
2.4M
Patients impacted
20-25
Ventures built annually
70+
Active ventures in our portfolio
80+
Healthcare experts
€160M+
Raised by NLC ventures

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director